Lenalidomide
Disease Related To Hematopoietic Stem Cell Transplant
Explore 55 assets in Disease Related To Hematopoietic Stem Cell Transplant →Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Stanford University
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06461988CT.gov Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma | — | Recruiting | — | — | — |
NCT03225417CT.gov Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease. | — | Active Not Recruiting | — | — | — |
NCT02420860CT.gov Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT01718743CT.gov Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Disease Related To Hematopoietic Stem Cell Transplant
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Lenalidomide (this asset) | Stanford University | P2 | BB · 66 |
| Busulfanum | Institute of Hematology & Blood Diseases Hospital, China | P3 | BBB |
| Cyclophosphamide | The First Affiliated Hospital of Soochow University | P3 | BBB |
| Nivestim | National Cancer Institute (NCI) | P2/3 | BBB |
| Decitabine | Chinese PLA General Hospital | P4 | BBB |
| Rituximab | M.D. Anderson Cancer Center | P2 | BBB |
| Cyclosporin A | The First Affiliated Hospital of Soochow University | P4 | BB |
| Tacrolimus | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | P3 | BB |
| Thiotepa | medac GmbH | P2 | BB |
+42 more in the Disease Related To Hematopoietic Stem Cell Transplant cohort
Other indications for Lenalidomide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult T-Cell Leukemia/Lymphoma | — | P2 | BBB · 74 |
| Plasma Cell Neoplasm | — | P3 | BBB · 72 |
| B-Cell Non-Hodgkin Lymphoma | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Lenalidomide in Disease Related To Hematopoietic Stem Cell Transplant. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/lenalidomide-disease-related-to-hematopoietic-stem-cell-transplant
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →